Applications published 6 July 2011
Selected patent applications from the weekly European Patents Bulletin
- Eye drop with diflupredinate for macular oedema treatment
Yamagata University 2340014*
- Controllable therapeutic system
LTS Lohmann Therapie-Systeme 2340015*
- Topical formulation of 3-(2,2,2-trimethy;hydrazinium) propionate dihydrate
Grindeks 2340016*
- Treatment of adrenal insufficiency
Diurnal 2340017*
- Water insoluble polymer: starch-based coatings for colon targeting
Roquette Freres 2340018*
- Water insoluble polymer: indigestible water-soluble polysaccharide film coatings for colon targeting
Roquette Freres 2340019*
- Manganese and cobalt complexes, their preparation and use
Universita’ Degli Studi di Firenze 2340020*
- Substituted pyrrolidine-2-carboxamides
F Hoffmann-La Roche 2340021*
- Combination therapy for tuberculosis
Pfizer; The Johns Hopkins University 2340022*
- The TRPVL antagonist SB-705498 for treating rhinitis
Glaxo Group 2340023*
- Use of 3,11B-cis-dihydrobenzanine in the treatment of dementia and associated cognitive deficit
Biovail Laboratories International (Barbados) 2340024*
- CGRP receptor antagonists
Merck Sharp & Dohme 2340025*
- A deproteinised calf blood preparation for use in prevention or treatment of diabetic peripheral polyneuropathy
Nycomed Austria 2340026*
- Methods and compsns for the treatment of cancer
Bionovo 2340027*
- Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
The Trustees of the University of Pennsylvania; Ritis, Konstantinos 2340028*
- Macrocyclic hepatitis C serine protease inhibitors
Enanta Pharmaceuticals; Abbott Laboratories 2340029*
- Methods, systems and compsns for calpain inhibition
Henry Ford Health System 2340030*
- Use of GDF traps to increase red blood cell levels
Acceleron Pharma 2340031*
- Pharmaceutical compsn for preventing or treating chronic obstructive pulmonary disease
Daewong 2340032*
- Preparation comprising insulin, nicotinamide and an amino acid
Novo Nordisk 2340033*
- Radioprotectants targeting thrombospondin-1 and CD47
The United States of America, as represented by the Secretary, Department of Heath & Human Services 2340034*
- Treatment of fructose malabsorption
Sciotec Diagnostic Technologies 2340035*
- Induction of mucosal immune responses by mucosal delivery pentabody complex (MDPC)
Dow Agrosciences; National Research Council of Canada 2340036*
- Methods for determining the levels of TGF in a compsn
Mead Johnson Nutrition 2340037*
- Biochemically stabilised HIV-1 env trimer vaccine
Children’s Medical Centre Corp; Beth Israel Deaconess Medical Centre 2340038*
- Use of IL-20 antagonists for treating rheumatoid arthritis and osteoporosis
National Cheng Kung University 2340039*
- Modulation of axon degeneration
F Hoffmann-La Roche 2340040*
- Porphyrazine optical and dual optical/MR contrast and therapeutic agents
Hoffmann/Barrett 2340041*
- Methods and compsns for the treatment of cancer
Translational Cancer Drugs Pharma 2340042*
- Topical compsn comprising a combination of at least two penetration enhancing agents
Moberg Derma 2340043*
- PEGylated opioids with low potential for abuse
Nektar Therapeutics 2340044*
- Polymer conjugates of protegrin peptides
Nektar Therapeutics 2340045*
- Peptide conjugates of ziconotide peptides
Nektar Therapeutics 2340046*
- Polymer conjugates of KISS1 peptides
Nektar Therapeutics 2340047*
- Polymer conjugates of biphalin peptides
Nektar Therapeutics 2340048*
- Method of acylated a peptide or protein
Novo Nordisk 2340049*
- Polymer conjugates of AOD-like peptides
Nektar Therapeutics 2340050*
- Drug carrier providing MRI contrast enhancement
Koninklijke Philips Electronics 2340051*
- Delivery device for use with a therapeutic drug
F Hoffmann-La Roche 2340070*
- Organic compounds for applications in bacterial infections treatment
Novartis 2340241*
- Compounds for treating opthalmic diseases and disorders
Acucela 2340242*
- Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
Boehringer Ingelheim International 2340243*
- Compounds and methods of use
Xi, Ning 2340244*
- A novel betaine cocrystal of eplarestat
Bionevia Pharmaceuticals 2340245*
- Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-methyl)-sulfamide
Janssen Pharmaceutica 2340246*
- Quinolizidinone M1 receptor positive allosteric modulators
Merck Sharp & Dohme 2340247*
- Methods and compsns for modulating IRE1, SRC and ABL activity
The Regents of the University of California 2340248*
- Poly-heteroaryl derivatives for the treatment of cancer
Institut Curie; Centre National de la Recherche Scientifique; Museum National d’Histoire Naturelle 2340249*
- Selective glycosidase inhibitors and uses thereof
Simon Fraser University 2340250*